Drug Details
General Information of the Drug (ID: DR3599) | ||||
---|---|---|---|---|
Name |
Atorvastatin
|
|||
Synonyms |
atorvastatin; 134523-00-5; Cardyl; Lipitor; ATORVASTATIN CALCIUM; Torvast; (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid; UNII-A0JWA85V8F; 110862-48-1; CI 981; Lipitor (TN); Tozalip; Xavator; A0JWA85V8F; CHEMBL1487; (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; CHEBI:39548; 134523-00-5 (free acid); (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 134523-03-8; Atorvastatin [INN:BAN]; (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (R-(R*,R*))-; Atorvastatin calcium salt; atorvastatina; atorvastatine; atrovastin; Atofast; Atorcor; Atorlip; Lipilou; Lipinon; Atorin; Ator; Lipitor(TM); (3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; Atorvastatin (INN); Sortis (TN); CCRIS 7159; MFCD00899261; C33H35FN2O5; HSDB 7039; NCGC00159458-03; atorvastatinum; rel-Atorvastatin; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; Atorvastatin & Primycin; DSSTox_CID_9868; SCHEMBL3831; DSSTox_RID_78825; DSSTox_GSID_29868; BIDD:GT0336; Atorvastatin (Relative Stereo); GTPL2949; DTXSID8029868; BDBM22164; DTXSID60274003; HMS3715L05; HMS3886C20; Lipilou; Tozalip; Torvast; Cardyl; ACT03225; HY-B0589; ZINC3920719; Tox21_302417; s5715; AKOS000281127; AC-9386; CCG-221172; DB01076; MCULE-2368532812; MRF-0000761; NCGC00159458-02; NCGC00159458-20; NCGC00255181-01; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (betaR,deltaR)-; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; AS-35260; H942; CAS-134523-00-5; C06834; D07474; S-2492; Y-8867; 28052-EP2269989A1; 28052-EP2269990A1; 28052-EP2270011A1; 28052-EP2270505A1; 28052-EP2272825A2; 28052-EP2272841A1; 28052-EP2280001A1; 28052-EP2284158A1; 28052-EP2287165A2; 28052-EP2287166A2; 28052-EP2292600A1; 28052-EP2292620A2; 28052-EP2295406A1; 28052-EP2295409A1; 28052-EP2295417A1; 28052-EP2295422A2; 28052-EP2298731A1; 28052-EP2298742A1; 28052-EP2298745A1; 28052-EP2298769A1; 28052-EP2298772A1; 28052-EP2298776A1; 28052-EP2298779A1; 28052-EP2301923A1; 28052-EP2301931A1; 28052-EP2301936A1; 28052-EP2308839A1; 28052-EP2308878A2; 28052-EP2314588A1; 523A005; Q668093; SR-01000872702; SR-01000872702-1; BRD-K69726342-001-02-6; UNII-36TN91XZ0V component XUKUURHRXDUEBC-KAYWLYCHSA-N; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (beta-R,delta-R)-;
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Cardiovascular disease [ICD-11: BA00-BE2Z] | Approved | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C33H35FN2O5
|
|||
PubChem CID | ||||
Canonical SMILES |
CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4
|
|||
InChI |
1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
|
|||
InChIKey |
XUKUURHRXDUEBC-KAYWLYCHSA-N
|
|||
CAS Number |
CAS 134523-00-5
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Ferulic acid | Ferula sinkiangensisK | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | IL6 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
In-vivo Model | Male Swiss albino mice were given a diet containing high fat. | |||||
Experimental
Result(s) |
Simultaneous treatment with AS, F and their combination protected against HFD induced weight gain and oxidative stress. | |||||
Gamma tocotrienol | Bixa orellana | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [3] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Cleavage | CASP3 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Cleavage | PARP1 | Molecule Info |
Pathway MAP
|
||
Biological
Regulation |
Induction | Cell cycle arrest in G0/G1 phase | ||||
Increase | DNA fragmentation | |||||
In-vitro Model | HT29 | CVCL_A8EZ | Colorectal adenocarcinoma | Mus musculus | ||
HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Atorvastatin with gamma-tocotrienol and celecoxib exhibited a strong synergy against human colon cancer cells in causing cell cycle arrest and apoptosis. | |||||
Metformin | Galega officinalis | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [5] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vivo Model | Clinical trial | |||||
Experimental
Result(s) |
Use of statin and metformin provides a synergistic improvement in gastrointestinal malignancies outcomes. | |||||
Phloretin | Prunus armeniaca | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [6] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | CCNB1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | MYT1 | Molecule Info | |||
Down-regulation | Phosphorylation | POLD1 | Molecule Info |
Pathway MAP
|
||
In-vitro Model | SW620 | CVCL_0547 | Colon adenocarcinoma | Homo sapiens | ||
HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Phloretin and Atorvastatin produce a powerful synergistic interaction in suppressing colon cancer cell growth. This process was accomplished via the synergistic induction of apoptosis and the arrest of the cell cycle at the G2/M checkpoint, which resulted from downregulated cdc2 activation following combined treatment. | |||||
Tanshinone IIA | Salvia miltiorrhiza | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [7] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vivo Model | Six-week old male ApoE KO mice were used in this study. | |||||
Experimental
Result(s) |
Tan in conjunction with Ato represents an effective combination therapy to comprehensively combat atherogenesis in ApoE / mice by reducing plaque size and stabilizing vulnerable atheromatous plaques. | |||||
Tocotrienols | Trachycarpus fortunei | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [8] | |||||
Detail(s) |
Combination Info
![]() |
|||||
In-vitro Model | HT29 | CVCL_A8EZ | Colorectal adenocarcinoma | Mus musculus | ||
HCT 116 | CVCL_0291 | Colon carcinoma | Homo sapiens | |||
Experimental
Result(s) |
The synergistic actions of Gamma-T3 and ATST could be attributed to their mediation of 3-hydroxy-3-methyl-glutaryl-CoA reductase, and the subsequent inhibition of protein geranylgeranylation. | |||||
Tretinoin | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [9] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Down-regulation | Expression | CDH2 | Molecule Info |
Pathway MAP
|
|
In-vivo Model | MOG35-55 in female C57BL/6 mice were used in this study. | |||||
Experimental
Result(s) |
Combined atorvastatin and ATRA have immunomodulatory synergistic benefits. | |||||
β. A List of Natural Product(s) Able to Decrease the Adverse Effect of This Drug | ||||||
Glatiramer acetate | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [10] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Molecule(s)
Regulation |
Up-regulation | Expression | IL10 | Molecule Info |
Pathway MAP
|
|
Down-regulation | Expression | IL12A | Molecule Info |
Pathway MAP
|
||
Down-regulation | Expression | TNF | Molecule Info |
Pathway MAP
|
||
In-vivo Model | Female (PL/J * SJL/J)mice were immunized with MBP Ac1-11 (100 ug) to establish the animal model. | |||||
Experimental
Result(s) |
Monocytes treated with the combination of suboptimal doses of atorvastatin and GA secreted an antiinflammatory type II cytokine pattern and, when used as APCs, promoted Th2 differentiation of naive myelin-specific T cells. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | HMG-CoA reductase (HMGCR) | Molecule Info | [11] | |
BioCyc | Superpathway of geranylgeranyldiphosphate biosynthesis I (via mevalonate) | Click to Show/Hide | ||
2 | Superpathway of cholesterol biosynthesis | |||
3 | Mevalonate pathway | |||
KEGG Pathway | Terpenoid backbone biosynthesis | Click to Show/Hide | ||
2 | Metabolic pathways | |||
3 | Biosynthesis of antibiotics | |||
4 | AMPK signaling pathway | |||
5 | Bile secretion | |||
NetPath Pathway | IL5 Signaling Pathway | Click to Show/Hide | ||
2 | TGF_beta_Receptor Signaling Pathway | |||
3 | TSH Signaling Pathway | |||
Panther Pathway | Cholesterol biosynthesis | Click to Show/Hide | ||
Pathwhiz Pathway | Steroid Biosynthesis | Click to Show/Hide | ||
WikiPathways | Statin Pathway | Click to Show/Hide | ||
2 | Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
3 | Activation of Gene Expression by SREBP (SREBF) | |||
4 | SREBF and miR33 in cholesterol and lipid homeostasis | |||
5 | Integrated Breast Cancer Pathway | |||
6 | SREBP signalling | |||
7 | Cholesterol Biosynthesis |











